Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Galera Therapeutics Inc GRTX

Healthcare Biotechnology
Galera Therapeutics, Inc. is a biopharmaceutical company focused on developing a pipeline of novel, therapeutic candidates that have the potential to transform radiotherapy in cancer. The Company’s lead product candidate, avasopasem manganese (avasopasem), is a highly selective small molecule dismutase mimetic that the Company is developing for the reduction of severe oral mucositis (SOM) in... see more

Recent & Breaking News (OTCPK:GRTX)

Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis

GlobeNewswire December 12, 2022

Galera to Present at Piper Sandler Annual Healthcare Conference

GlobeNewswire November 22, 2022

Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates

GlobeNewswire November 9, 2022

Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting

GlobeNewswire October 26, 2022

Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting

GlobeNewswire September 26, 2022

Galera to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 6, 2022

Galera Appoints Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer

GlobeNewswire September 1, 2022

Galera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates

GlobeNewswire August 9, 2022

Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC

GlobeNewswire June 29, 2022

Galera to Present at Jefferies Healthcare Conference

GlobeNewswire June 2, 2022

Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem

GlobeNewswire May 26, 2022

Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates

GlobeNewswire May 16, 2022

Galera Announces Plan to Submit Avasopasem NDA by Year End

GlobeNewswire May 16, 2022

Galera Announces Topline Results from Phase 2a AESOP Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis

GlobeNewswire May 2, 2022

Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire April 27, 2022

Galera Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates

GlobeNewswire March 10, 2022

Galera to Present at H.C. Wainwright BioConnect Conference

GlobeNewswire January 6, 2022

Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem

GlobeNewswire December 14, 2021

Galera to Present at Two Upcoming Investor Conferences in November

GlobeNewswire November 15, 2021

Galera Reports Third Quarter 2021 Financial Results and Recent Corporate Updates

GlobeNewswire November 10, 2021